Your browser is no longer supported. Please, upgrade your browser.
RPRX Repros Therapeutics Inc. monthly Stock Chart
RPRX [NASD]
Repros Therapeutics Inc.
Index- P/E- EPS (ttm)-1.05 Insider Own0.50% Shs Outstand24.32M Perf Week-5.56%
Market Cap41.34M Forward P/E- EPS next Y-0.83 Insider Trans35.72% Shs Float24.17M Perf Month15.65%
Income-25.50M PEG- EPS next Q-0.20 Inst Own34.50% Short Float2.85% Perf Quarter-29.17%
Sales- P/S- EPS this Y13.50% Inst Trans0.64% Short Ratio1.38 Perf Half Y63.46%
Book/sh0.59 P/B2.88 EPS next Y-10.70% ROA-105.30% Target Price3.50 Perf Year-77.36%
Cash/sh0.66 P/C2.58 EPS next 5Y27.90% ROE-117.90% 52W Range0.80 - 8.96 Perf YTD40.50%
Dividend- P/FCF- EPS past 5Y-15.20% ROI- 52W High-80.13% Beta-0.30
Dividend %- Quick Ratio7.80 Sales past 5Y- Gross Margin- 52W Low122.50% ATR0.13
Employees26 Current Ratio7.80 Sales Q/Q- Oper. Margin- RSI (14)52.74 Volatility6.55% 7.92%
OptionableYes Debt/Eq0.00 EPS Q/Q43.30% Profit Margin- Rel Volume0.46 Prev Close1.70
ShortableYes LT Debt/Eq0.00 EarningsAug 10 BMO Payout- Avg Volume498.81K Price1.78
Recom2.70 SMA203.85% SMA50-0.01% SMA200-2.34% Volume224,470 Change4.71%
Oct-30-15Downgrade BofA/Merrill Neutral → Underperform
May-14-13Reiterated Ascendiant Capital Markets Strong Buy $19 → $23
Mar-28-13Reiterated Ladenburg Thalmann Buy $18 → $25
Nov-15-12Reiterated Ascendiant Capital Markets Strong Buy $12 → $18
Oct-09-12Reiterated Ladenburg Thalmann Buy $15 → $18
Apr-10-12Initiated Ascendiant Capital Markets Strong Buy $6
Mar-16-11Reiterated Ladenburg Thalmann Buy $6 → $9
Jul-19-16 04:12PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure +16.57%
Jul-01-16 05:19PM  5 Top Biotech Performers of 2016
04:07PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-24-16 08:54AM  Research Report Initiated on Select Biotechnology Equities -7.65%
Jun-07-16 01:44PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
Jun-02-16 04:08PM  6 Biotechs Seriously on the Move at 24/7 Wall St. +18.34%
Jun-01-16 04:23PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -8.65%
04:01PM  Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men GlobeNewswire
May-19-16 01:04PM  REPROS THERAPEUTICS INC. Financials
May-18-16 04:18PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
04:01PM  Repros Reports Positive Clinical Data for Oral Proellex® in Women With Severe Menstrual Bleeding Due to Uterine Fibroids GlobeNewswire
May-16-16 04:56PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers
04:00PM  Repros Announces the Appointment of Mr. Patrick Fourteau as Chairman of the Board GlobeNewswire
May-11-16 09:01AM  Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus
May-10-16 09:19AM  Repros Therapeutics reports 1Q loss
09:16AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
09:15AM  Repros Therapeutics Inc.® Reports First Quarter 2016 Financial Results GlobeNewswire
May-04-16 08:56AM  Will Repros Therapeutics (RPRX) Continue to Surge Higher? Zacks
May-03-16 09:25AM  Repros (RPRX) Q1 Earnings: What's in Store for the Stock? Zacks
Apr-19-16 10:05AM  These Four Biotech Stocks Are Trading With Massive Volume Today Accesswire +12.19%
Apr-18-16 02:26PM  Why Disney (DIS), Amedica (AMDA), Cvent (CVT), UniPixel (UNXL), and Repros Therapeutics (RPRX) Are Spiking Today at Insider Monkey +22.91%
12:35PM  Trending Stocks: Investors Have Found Interest In These Four Nasdaq Stocks on Monday Accesswire
09:02AM  [$$] Clinical Development News, April 11-15 at The Wall Street Journal
Apr-14-16 03:01PM  Repros to drop testosterone drug in U.S. if key study fails +18.67%
12:07PM  Trending Stocks: Thursday's Top Trading Stock Investors Have Followed Accesswire
11:38AM  Whats the Deal With These 5 Stocks on the Move Today? at Insider Monkey
09:47AM  Repros Therapeutics given time to rally
08:30AM  4 Small Cap Stocks That Have To Be On Your Watchlist Today Accesswire
Apr-13-16 01:27PM  Repros Therapeutics (RPRX) Announces Significant Data for Proellex Phase 2 Meeting with the FDA to Jointly Discuss Plans for Phase 3 Accesswire +174.39%
12:30PM  Repros Reveals Positive Data on Proellex for Uterine Fibroids
10:49AM  These Small Cap Stocks Are Getting Big Time Attention Today Accesswire
Apr-12-16 04:02PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -5.75%
04:01PM  Repros Reports Positive Clinical Data for Vaginal Proellex® in Women With Severe Menstrual Bleeding Due to Uterine Fibroids GlobeNewswire
Mar-16-16 05:05PM  Repros Gives EU Update on Secondary Hypogonadism Drug
Mar-15-16 04:02PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -6.73%
04:01PM  Repros Announces Initiation of Formal Approval Process by the European Medicines Agency GlobeNewswire
09:40AM  Repros Incurs Narrower-than-Expected Loss in Q4, Shares Up
Mar-14-16 09:33AM  Repros Therapeutics reports 4Q loss
09:16AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
09:15AM  Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2015 Financial Results GlobeNewswire
Feb-17-16 02:40PM  Repros Updates on Proof-of-Concept Study on Enclomiphene +8.14%
11:40AM  LPCN: Encouraging Top-Line Results from PK Dose Finding Study of LPCN 1107; Raising Price Target
Feb-16-16 04:03PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
04:01PM  Repros Completes Randomization of Enclomiphene Phase 2 Proof of Concept Study in Obese Secondary Hypogonadal Men
Feb-09-16 04:30PM  Repros, FDA Meet to Discuss Issues of Enclomiphene's CRL
Feb-08-16 04:09PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -12.62%
04:01PM  Repros Holds Meeting With FDA to Discuss Complete Response Letter for Enclomiphene in the Treatment of Secondary Hypogonadism GlobeNewswire
Jan-19-16 11:22AM  Smart Money Highlights Oversold Stocks in Small Cap Biotechs Accesswire -6.06%
Jan-11-16 09:16AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
09:15AM  Repros Announces Court of Appeals Affirmation of Summary Judgment in Favor of the Company GlobeNewswire
Jan-06-16 04:21PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers -5.51%
Jan-04-16 04:06PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +7.44%
04:05PM  Repros Updates Enclomiphene Program GlobeNewswire
Dec-22-15 04:25PM  Repros Provides Update on Proellex Program, Data by 3Q16
Dec-21-15 04:07PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
04:05PM  Repros Updates Proellex® Program GlobeNewswire
Dec-09-15 01:50PM  Is Evolution Petroleum Corporation (EPM) Going to Burn These Hedge Funds? at Insider Monkey
Dec-03-15 09:30AM  The Zacks Analyst Blog Highlights: Repros Therapeutics, AbbVie, Amgen, XOMA and Gilead
Dec-02-15 04:25PM  Repros Hits 52-Week Low after Enclomiphene Receives CRL
02:09PM  Biotech Stock Roundup: Repros Tanks on CRL, AbbVie Multiple Myeloma Drug Approved
Dec-01-15 01:42PM  Repros (RPRX) Stock Plummets After FDA Rejects Hypogonadism Drug Trial Results at TheStreet -27.50%
09:51AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
09:50AM  Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene GlobeNewswire
Nov-30-15 08:00AM  Repros Therapeutics (RPRX) Looks Good: Stock Soars 45.1% -5.51%
Nov-29-15 03:30PM  4 Stocks Under $10 to Trade for Big Breakouts at TheStreet
Nov-27-15 01:36PM  Why Repros Therapeutics Inc (RPRX) Was One Of Black Fridays Biggest Gainers at Insider Monkey +45.14%
09:30AM  The Zacks Analyst Blog Highlights: BioMarin, Amgen, Vertex, Gilead, Biogen and Repros
Nov-25-15 10:15AM  Biotech Stock Roundup: KaloBios Soars as Shkreli Steps In, FDA Panel Not Convinced about BioMarin Drug
Nov-17-15 04:10PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
Nov-16-15 11:09AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers
Nov-13-15 04:30PM  Repros Provides Update on Phase IIb Study on Proellex
Nov-12-15 04:09PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
04:05PM  Repros Therapeutics Completes Randomization of Phase 2b Study of Vaginal Proellex(R) in Women With Symptomatic Uterine Fibroid Bleeding GlobeNewswire
Nov-10-15 11:00AM  Repros' Q3 Loss Narrower than Expected, Pipeline in Focus
Nov-09-15 10:47AM  Repros' (RPRX) Q3 Loss a Penny Narrower than Expected -6.74%
09:25AM  Repros Therapeutics reports 3Q loss
09:16AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition
09:15AM  Repros Therapeutics Inc.(R) Reports Third Quarter 2015 Financial Results GlobeNewswire
Nov-05-15 03:50PM  What's in Store for Repros (RPRX) this Earnings Season? -9.42%
09:30AM  The Zacks Analyst Blog Highlights: AbbVie, Amgen, Dyax, Repros and Gilead
Nov-04-15 10:41AM  Biotech Stock Roundup: AbbVie's Humira Remains Strong, Shire to Buy Dyax +6.11%
Nov-03-15 09:10AM  How The 'Low T' Wars Cast A Shadow Over Repros' Testosterone Alternative at Forbes +7.78%
Nov-01-15 09:10AM  4 Key FDA Decisions Expected in November and December at 24/7 Wall St.
Oct-30-15 11:20AM  Repros Hits 52-Week Low, FDA Delays Enclomiphene Meeting -17.79%
Oct-29-15 04:09PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure -55.56%
03:12PM  Repros Therapeutics Announces Cancellation of FDA Advisory Committee Meeting to Review Enclomiphene for the Treatment of Secondary Hypogonadism GlobeNewswire
Oct-28-15 09:57AM  Biotech Stock Roundup: Biogen Tops Estimates, FDA Approves Alexion's Strensiq
Oct-15-15 04:00PM  LPCN: Files NDA for LPCN 1021 with FDA Approval on Track for 2016
Sep-29-15 09:52AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
Aug-13-15 08:10PM  10-Q for Repros Therapeutics, Inc. at Company Spotlight
Aug-11-15 10:30AM  Repros Incurs Narrower Y/Y Loss in Q2, Pipeline in Focus - Analyst Blog
Aug-10-15 10:33AM  Repros (RPRX) Reports Narrower Y/Y Loss in Q2 - Tale of the Tape +6.91%
09:30AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition
09:22AM  Repros Therapeutics reports 2Q loss
09:15AM  Repros Therapeutics Inc.(R) Reports Second Quarter 2015 Financial Results GlobeNewswire
Aug-07-15 02:40PM  What to Expect from Repros (RPRX) this Earnings Season? - Analyst Blog
Jul-09-15 01:58PM  3 Stocks Under $10 Triggering Breakout Trades at TheStreet
Jun-18-15 02:31PM  3 Biotech Stocks Under $10 to Trade for Breakouts at TheStreet
Jun-09-15 04:40PM  Repros' Enclomiphene to Face FDA Advisory Panel in November - Analyst Blog
06:03AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
Repros Therapeutics Inc., a biopharmaceutical company, focuses on the development of new drugs to treat hormonal and reproductive system disorders for male and female in the United States. Its product portfolio includes enclomiphene, an oral therapy, which is in Phase III clinical trials for the treatment of low testosterone levels due to secondary hypogonadism; and Proellex that is in Phase IIB clinical trials for the treatment of symptoms associated with uterine fibroids, as well as in Phase II clinical trial for the treatment of endometriosis. The company has a license agreement with the National Institutes of Health to develop and commercialize Proellex. Repros Therapeutics Inc. was founded in 1987 and is based in The Woodlands, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PODOLSKI JOSEPHPresident and CEOFeb 18Buy0.9310,0009,30087,422Feb 19 04:06 PM
Anderson KatherineChief Financial OfficerJan 27Buy1.0812,00012,96023,875Jan 28 04:12 PM
Wernicke J. F.Chief Medical OfficerJan 25Buy1.1110,00011,12610,000Jan 28 04:12 PM
PODOLSKI JOSEPHPresident and CEOJan 07Buy1.143,5003,99077,422Jan 07 04:44 PM
PODOLSKI JOSEPHPresident and CEOJan 06Buy1.208,1779,80473,922Jan 07 04:44 PM